197 related articles for article (PubMed ID: 29843988)
1. Oncologic Safety of Gonadotropin-Releasing Hormone Agonist for Ovarian Function Protection During Breast Cancer Chemotherapy.
Kim HJ; Lee MH; Lee JE; Park S; Lee ES; Kang YJ; Shin HN; Kim SI; Lee JH; Im SA; Ahn SH; Lee KS; Sohn J; Kim S; Nam SJ; Han W
Clin Breast Cancer; 2018 Oct; 18(5):e1165-e1172. PubMed ID: 29843988
[TBL] [Abstract][Full Text] [Related]
2. Ovarian function preservation with GnRH agonist in young breast cancer patients: does it impede the effect of adjuvant chemotherapy?
Kim J; Kim M; Lee JH; Lee H; Lee SK; Bae SY; Jun SY; Kil WH; Lee JE; Kim SW; Nam SJ
Breast; 2014 Oct; 23(5):670-5. PubMed ID: 25088482
[TBL] [Abstract][Full Text] [Related]
3. Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a meta-analysis of randomized controlled trials.
Yang B; Shi W; Yang J; Liu H; Zhao H; Li X; Jiao S
Breast; 2013 Apr; 22(2):150-157. PubMed ID: 23298851
[TBL] [Abstract][Full Text] [Related]
4. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.
Moore HC; Unger JM; Phillips KA; Boyle F; Hitre E; Porter D; Francis PA; Goldstein LJ; Gomez HL; Vallejos CS; Partridge AH; Dakhil SR; Garcia AA; Gralow J; Lombard JM; Forbes JF; Martino S; Barlow WE; Fabian CJ; Minasian L; Meyskens FL; Gelber RD; Hortobagyi GN; Albain KS;
N Engl J Med; 2015 Mar; 372(10):923-32. PubMed ID: 25738668
[TBL] [Abstract][Full Text] [Related]
5. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data.
Lambertini M; Moore HCF; Leonard RCF; Loibl S; Munster P; Bruzzone M; Boni L; Unger JM; Anderson RA; Mehta K; Minton S; Poggio F; Albain KS; Adamson DJA; Gerber B; Cripps A; Bertelli G; Seiler S; Ceppi M; Partridge AH; Del Mastro L
J Clin Oncol; 2018 Jul; 36(19):1981-1990. PubMed ID: 29718793
[TBL] [Abstract][Full Text] [Related]
6. Protecting Ovaries During Chemotherapy Through Gonad Suppression: A Systematic Review and Meta-analysis.
Elgindy E; Sibai H; Abdelghani A; Mostafa M
Obstet Gynecol; 2015 Jul; 126(1):187-95. PubMed ID: 26241272
[TBL] [Abstract][Full Text] [Related]
7. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials.
Del Mastro L; Ceppi M; Poggio F; Bighin C; Peccatori F; Demeestere I; Levaggi A; Giraudi S; Lambertini M; D'Alonzo A; Canavese G; Pronzato P; Bruzzi P
Cancer Treat Rev; 2014 Jun; 40(5):675-83. PubMed ID: 24360817
[TBL] [Abstract][Full Text] [Related]
8. Gonadotropin-releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta-analysis.
Senra JC; Roque M; Talim MCT; Reis FM; Tavares RLC
Ultrasound Obstet Gynecol; 2018 Jan; 51(1):77-86. PubMed ID: 29055060
[TBL] [Abstract][Full Text] [Related]
9. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial.
Leonard RCF; Adamson DJA; Bertelli G; Mansi J; Yellowlees A; Dunlop J; Thomas GA; Coleman RE; Anderson RA;
Ann Oncol; 2017 Aug; 28(8):1811-1816. PubMed ID: 28472240
[TBL] [Abstract][Full Text] [Related]
10. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma.
Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Rea S
Cancer; 2006 Feb; 106(3):514-23. PubMed ID: 16388519
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women.
Chen H; Li J; Cui T; Hu L
Cochrane Database Syst Rev; 2011 Nov; (11):CD008018. PubMed ID: 22071842
[TBL] [Abstract][Full Text] [Related]
12. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
Del Mastro L; Boni L; Michelotti A; Gamucci T; Olmeo N; Gori S; Giordano M; Garrone O; Pronzato P; Bighin C; Levaggi A; Giraudi S; Cresti N; Magnolfi E; Scotto T; Vecchio C; Venturini M
JAMA; 2011 Jul; 306(3):269-76. PubMed ID: 21771987
[TBL] [Abstract][Full Text] [Related]
13. Can ovarian suppression with gonadotropin-releasing hormone analogs (GnRHa) preserve fertility in cancer patients?
Rodriguez-Wallberg K; Turan V; Munster P; Oktay K
Ann Oncol; 2016 Feb; 27(2):357. PubMed ID: 26609009
[TBL] [Abstract][Full Text] [Related]
14. GnRH-analogues for ovarian protection in childhood cancer patients: how adult hypotheses are relevant in prepubertal females.
Osborne SE; Detti L
Curr Drug Targets; 2013 Jul; 14(8):856-63. PubMed ID: 23614679
[TBL] [Abstract][Full Text] [Related]
15. Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial.
Lambertini M; Boni L; Michelotti A; Gamucci T; Scotto T; Gori S; Giordano M; Garrone O; Levaggi A; Poggio F; Giraudi S; Bighin C; Vecchio C; Sertoli MR; Pronzato P; Del Mastro L;
JAMA; 2015 Dec 22-29; 314(24):2632-40. PubMed ID: 26720025
[TBL] [Abstract][Full Text] [Related]
16. A pilot study to assess the use of the gonadotrophin antagonist cetrorelix in preserving ovarian function during chemotherapy.
Whitehead J; Toledo MG; Stern CJ
Aust N Z J Obstet Gynaecol; 2011 Oct; 51(5):452-4. PubMed ID: 21810087
[TBL] [Abstract][Full Text] [Related]
17. Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival.
Zhang Y; Ji Y; Li J; Lei L; Wu S; Zuo W; Jia X; Wang Y; Mo M; Zhang N; Shen Z; Wu J; Shao Z; Liu G
Breast Cancer Res Treat; 2018 Apr; 168(3):679-686. PubMed ID: 29332135
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients.
Lambertini M; Boni L; Michelotti A; Magnolfi E; Cogoni AA; Mosconi AM; Giordano M; Garrone O; Arpino G; Poggio F; Cinacchi P; Bighin C; Fregatti P; Pronzato P; Blondeaux E; Del Mastro L;
J Natl Cancer Inst; 2022 Mar; 114(3):400-408. PubMed ID: 34850043
[TBL] [Abstract][Full Text] [Related]
19. Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain.
Turner NH; Partridge A; Sanna G; Di Leo A; Biganzoli L
Ann Oncol; 2013 Sep; 24(9):2224-35. PubMed ID: 23709175
[TBL] [Abstract][Full Text] [Related]
20. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial.
Elgindy EA; El-Haieg DO; Khorshid OM; Ismail EI; Abdelgawad M; Sallam HN; Abou-Setta AM
Obstet Gynecol; 2013 Jan; 121(1):78-86. PubMed ID: 23262931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
